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ABSTRACT
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of 
pathological complete response (pCR) and event-free survival (EFS) compared to 
neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer 
(BC). pCR in this setting is associated with improved EFS. Whether NCT preferentially 
improves EFS in comparison to NC followed by adjuvant trastuzumab initiated 
postoperatively (NCAT) has not been addressed. Using clinical data from women 
with HER2 positive BC treated at 7 European institutions between 2007 and 2010 we 
sought to investigate the impact on breast cancer outcomes of concomitant (NCT) 
versus sequential (NCAT) treatment in HER2 positive early BC. The unadjusted hazard 
ratio (HR) for event free survival with NCT compared with NCAT was 0.63 (95% 
CI 0.37–1.08; p = 0.091). Multivariable analysis revealed that treatment group, 
tumour size and ER status were significantly associated with EFS from diagnosis. 
In the whole group NCT was associated with a reduced risk of an event relative to 
NCAT, an effect that was confined to ER negative (HR: 0.25; 95% CI, 0.10–0.62; p = 
0.003) as opposed to ER positive tumours (HR: 1.07; 95% CI, 0.46–2.52; p = 0.869). 
HER2 positive/ER negative BC treated with NC gain greatest survival benefit when 
trastuzumab is administered in both the neoadjuvant and adjuvant period rather than 
in the adjuvant period alone. These data support the early introduction of targeted 
combination therapy in HER2 positive/ER negative BC.
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INTRODUCTION
Adjuvant trastuzumab (AT) improves overall 
survival (OS) in HER2-positive early breast cancer 
when administered concomitantly with, or sequentially 
after chemotherapy [1, 2]. In the neoadjuvant setting 
the addition of trastuzumab to chemotherapy (NCT) has 
been shown to increase pathological complete response 
(pCR) compared with neoadjuvant chemotherapy 
(NC) alone [3, 4, 5], and translated to a non-significant 
improvement in breast preservation favouring NCT over 
NC [6]. NCT also resulted in significant improvements 
in disease-free survival (DFS) [3] and event free survival 
(EFS) [4, 5] although very few patients in the NC 
control arms received AT in either study [0% and 17%] 
reflecting the standard of care at the time [3, 4]. These 
studies do not, therefore, address whether there is an 
advantage to commencing trastuzumab concomitantly 
with neoadjuvant chemotherapy or whether trastuzumab 
may be administered after completion of neoadjuvant 
chemotherapy and surgery with equal efficacy. We 
have previously reported that DFS may be inferior 
to the published data in a group of patients treated in 
the neoadjuvant setting where the trastuzumab was 
commenced postoperatively [7].
In the adjuvant setting, studies that employed 
concurrent versus sequential trastuzumab and 
chemotherapy were associated with lower hazard ratios 
for DFS, and the only negative adjuvant study used a 
sequential strategy [8]. However, only one study, North 
Central Cancer Treatment Group (NCCTG) N9831, 
directlty addressed the sequencing question; this 
randomised women to AC-paclitaxel chemotherapy with 
or without trastuzumab either in sequence or combination 
with the paclitaxel portion of the regimen. Improved 
DFS was observed in the concurrent vs sequential arm, 
although this did not reach prespecified levels of statistical 
significance [9]. Based on the suggested improved efficacy 
without any significant increase in toxicity, concurrent 
trastuzumab and taxane chemotherapy was suggested to 
be a new standard of care.
As the effect of sequencing trastuzumab within the 
context of neoadjuvant therapy has not been addressed 
in prospective trials we sought to compare the EFS and 
OS of patients treated with NCT versus those receiving 
sequential NCAT in a multicentre retrospective cohort.
RESULTS
In total, 236 eligible patients were identified, of 
whom 98 had received neoadjuvant chemotherapy with 
concomitant trastuzumab (NCT) the latter being completed 
post-operatively and 138 who received neoadjuvant 
chemotherapy alone with the trastuzumab commenced post-
operatively (NCAT). For all patients the planned duration 
of trastuzumab was one year. Baseline clinico-pathological 
features are summarised in Table 1. The groups were 
balanced in terms of age, histological type, tumour size and 
estrogen receptor (ER) status, but differed with regards to 
chemotherapy regimen and tumour grade.
The median time to surgery from diagnosis was 
5.72 months (IQR: 5.22–6.44). Time to surgery was 
significantly longer (p = 0.012) for the NCT group (5.95 
months; IQR 5.35–6.77) in comparison to the NCAT group 
(5.52 months; IQR 5.03–6.21), (Table 2). As expected, the 
time from diagnosis to loading dose of trastuzumab was 
significantly shorter for the NCT group (3.5 months, IQR 
2.96–4.04) as compared to NCAT group (8.4 months; IQR 
6.64–9.63), p < 0.001 (Table 2).
At the time of analysis, treatment had been 
completed in 185 (78.4%) patients, was still ongoing in 
13 (5.5%) and had been stopped before completion for 38 
(28%). Of those cases that stopped treatment prematurely; 
15 were due to cardiotoxicity (NCT 3 vs NCAT 12), 15 to 
relapse (NCT 4 vs NCAT 11), 2 to the patient’s decision 
(NCAT 1 vs NCT 1) and 3 for other reasons (NCT 1 vs 
NCAT 2). The status of trastuzumab treatment differed 
significantly between groups (p < 0.001) with a higher 
proportion still ongoing treatment in the NCT group and 
a higher proportion stopping before completion in the 
NCAT group (Table 2). The number of trastuzumab cycles 
received did not differ between groups.
At the median follow up of 53.7 months, a total of 
49 events and 39 deaths had occurred. Fewer events were 
seen in the NCT group than the NCAT group [NCT 15 
(31%) vs NCAT 34 (69%)] and of these events 43 (88%) 
were relapses; 14 (33%) in the NCT group and 29 (67%) 
in NCAT group. Of the 39 deaths, 33 (85%) were due to 
breast cancer and fewer had occurred in the NCT group 
than the NCAT group; 9 (23%) and 30 (77%), respectively.
5-year EFS from diagnosis was 69.6% (95% CI: 
51.5–82.0) in the NCT group and 59.3% (95% CI: 49.8–
67.6) in the NCAT group. The unadjusted hazard ratio 
for risk of an event in the NCT group compared with the 
NCAT group was 0.63 (95% CI 0.37–1.08; p = 0.091) 
(Figure 1A). 5-year OS from diagnosis was 83.3% (95% 
CI: 66.2–92.2) in the NCT group and 74% (95% CI: 65.0–
81.1) in the NCAT group. The unadjusted hazard ratio of 
death was 0.70 (95% CI 0.34–1.44; p = 0.333) (Figure 
1B). The HR for breast cancer-specific survival favoured 
NCT with cancer-specific survival at 5 years being greater 
in the NCT than in the NCAT group (Table 3).
With regard to ER status, 5-year EFS from diagnosis 
was 70.7% (95% CI: 70.7–79.2) in women with ER 
positive tumours and 56.5% (95% CI: 44.7–66.6) in those 
with ER negative tumours. The unadjusted hazard ratio 
for risk of an event in women with ER negative tumours 
as compared to those with ER positive tumours was 2.02 
(95% CI 1.26–3.26; p = 0.004). 5-year OS from diagnosis 
was 85.5% (95% CI: 75.3–91.7) in those with ER positive 
tumours and 69.1% (95% CI: 57.7–78.0) in those with ER 
negative tumours. The unadjusted hazard ratio for risk of 
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an event in those with ER negative tumours as compared 
to ER positive tumours was 2.97 (95% CI 1.59–5.56; 
p = 0.001). The HR for breast cancer-specific survival 
significantly favoured those women who had ER positive 
tumours (Table 4).
Total pCR was obtained in 45 (19.6%) cases (33% 
NCT and 10% NCAT) and was significantly associated 
with treatment, with those receiving NCT having increased 
odds of pCR relative to NCAT (OR: 4.39; 95% CI 2.18–
8.86; p = < 0.001).
In the whole population, achieving total pCR was 
associated with significantly improved EFS from surgery, 
with an unadjusted hazard ratio of 0.23 (95% CI 0.08–
0.64; p = 0.002) (Figure 2A). Total pCR was higher in 
women with ER negative tumours (23.4%) vs ER positive 
(16.4%) tumours, although this did not reach statistical 
significance (Table 4). However, EFS from surgery by ER 
status and pCR revealed a significant difference between 
survival curves (p < 0.001) (Figure 2B). Achieving total 
pCR was also associated with a significantly improved OS 
from surgery, with an unadjusted hazard ratio of 0.22 (95% 
CI 0.05–0.93; p = 0.0247) (Figure 3A). OS from surgery 
by ER status and pCR revealed a significant difference 
between survival curves (p < 0.0003) (Figure 3B). At 
surgery there was a significant difference in lymph node 
status between the two groups with a higher percentage of 
patients being node negative in the NCT group compared 
to the NCAT group; 68% and 39%, respectively (Table 5).
Multivariable analysis revealed that treatment group, 
tumour size and ER status were associated with EFS from 
diagnosis. NCT was associated with a reduced risk of an 
event relative to NCAT (HR: 0.48; 95% CI 0.26–0.89; 
p = 0.021), whereas larger tumours and a negative ER 
status were associated with a significantly increased risk of 
Table 1: Baseline demographics
Baseline Demographics
Variable All patients (n = 236) NCT (n = 98) NCAT (n = 138) p-value
Age 50.4 (10.9) 51.4 (11.0) 49.7 (10.8) 0.2506
Histological type
 IDC 223 (94.5) 93 (94.9) 130 (94.2)
 Other 13 (5.5) 5 (5.1) 8 (5.8) 0.529
Tumour size
 < 20 mm 16 (6.8) 3 (3.1) 13 (9.4)
 20–50 mm 146 (61.9) 62 (63.3) 84 (60.9)
 > 50 mm 57 (24.2) 25 (25.5) 32 (23.2)
 Inflammatory/
Others 17 (7.2) 8 (8.2) 9 (6.5) 0.278
Tumour grade
 1–2 75 (31.8) 21 (21.4) 54 (39.1)
 3 135 (59.2) 58 (57.2) 77 (55.8)
 Not Available 26 (11.0) 19 (19.4) 7 (5.1) <0.001
Estrogen receptor 
status
 Positive 124 (52.5) 50 (51.0) 74 (53.6)
 Negative 111 (47.0) 48 (49.0) 63 (45.7)
 Not Available 1 (0.4) 0 1 (0.7) 0.632
Chemotherapy 
regimen
 Anthracycline 98 (41.5) 26 (26.5) 72 (52.2)
 AnthracyclineTaxane 118 (50.0) 58 (59.2) 60 (43.5)
 Taxane 5 (2.1) 3 (3.1) 2 (1.5)
 Other 15 (6.4) 11 (11.2) 4 (2.9) <0.001
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an event (Figure 4A). The significant interaction between 
treatment group and ER status indicated that the effect of 
NCT vs NCAT differed by ER status; for patients with ER 
negative tumours, NCT was significantly associated with a 
reduced risk of an event relative to NCAT (HR: 0.25; 95% 
CI, 0.1–0.62; p = 0.003), which was not observed for those 
with ER positive tumours (HR: 1.07; 95% CI, 0.46–2.52; 
p = 0.869) (Figure 4B).
After adjusting for pCR, ER status and surgery 
type, treatment group had no effect on OS from surgery. 
However, it was seen that a negative ER status was 
associated with an increased risk of death relative to a 
positive ER status, whereas achieving a total pCR and 
undergoing a wide local excision (WLE) were associated 
with a reduced risk of death (Figure 5).
DISCUSSION
The concomitant use of trastuzumab with 
chemotherapy in the neoadjuvant setting is associated 
with an increased rate of pCR, however the effects on EFS 
and OS have been unclear when compared with delayed 
post-operative trastuzumab. No randomised study to date 
has compared the efficacy of pre- versus post-operative 
trastuzumab, and therefore to address this issue we present 
the first report of data comparing patients with HER2 
positive breast cancers treated in the neoadjuvant setting 
where HER2 directed therapy was either commenced 
concomitantly with chemotherapy or in a sequential 
fashion following neoadjuvant chemotherapy and surgery. 
The sequential versus concomitant use of trastuzumab 
described within this study reflects the initial use of AT 
as per the HERA trial design [1], and the later shift to a 
concomitant use following data regarding the efficacy 
and safety of concurrent neoadjuvant chemotherapy and 
trastuzumab [5, 6].
The pCR rate within this study for the NCT cohort 
was three-fold higher than the NCAT cohort, 33% versus 
10% respectively and is similar to rates observed in 
prospective studies [10–16]. The pCR rate was lower in the 
NCAT group as compared to previous prospective studies 
[3, 4, 11], and may reflect the more heterogeneous nature 
of the chemotherapy administered and the fact that not all 
patients received a sequential anthracycline and taxane 
regimen. Women with ER negative tumours experienced a 
higher rate of pCR than those with ER positive tumours. 
This is consistent with non-randomised studies of HER2 
directed therapy [17–19] as well as randomised studies 
which have investigated chemotherapy alone versus 
chemotherapy plus trastuzumab [3], trastuzumab versus 
lapatinib [20], and trastuzumab versus lapatinib or doublet 
HER2 targeted therapy [10, 12, 13, 21]. In our study, pCR 
was associated with a significant benefit with regard to EFS 
and OS from surgery. These data being consistent with 
those from retrospective analyses, nonrandomised phase II 
studies, randomised studies and meta-analyses [10, 14, 15, 
18, 22]. pCR following chemotherapy plus trastuzumab, 
lapatinib or the doublet has been shown to be a strong 
predictor for OS [11, 14, 15], while NOAH reported EFS 
to be strongly associated with pCR in patients receiving 
trastuzumab [5]. A recent meta-analysis of randomised 
neoadjuvant trials found that the effects of pCR on EFS was 
more marked in the HER2 positive cases with the strength of 
the association increased in the hormone receptor negative 
Table 2: Summary of follow-up time, surgery and trastuzumab treatment
Overall NCT NCAT p
Follow-up 53.7 (41.7, 68.8) 44.8 (37.0, 53.9) 61.5 (50.3, 78.5)
Time to first traz 6.04 (3.52, 8.71) 3.45 (2.96, 4.04) 8.38 (6.64, 9.63) <0.001
Time to surgery 5.72 (5.22, 6.44) 5.95 (5.35, 6.77) 5.52 (5.03, 6.21) 0.012
Trastuzumab Status:
 Completed 185 (78.4) 78 (80.0) 107 (77.5)
 Ongoing 13 (5.5) 11 (11.2) 2 (1.5)
 Stopped 38 (16.1) 9 (9.2) 29 (21.0) <0.001
Reason for stopping:
 Cardiotoxicity 15 (39.5) 3 (33.3) 12 (41.4)
 Patient’s decision 2 (5.3) 1 (11.1) 1 (3.5)
 Relapse 15 (39.5) 4 (44.4) 11 (37.9)
 Other 3 (7.9) 1 (11.1) 2 (6.9)
 Unknown 3 (7.9) 0 3 (10.3) 0.712
Number of 
Trastuzumab cycles: 18 (1–36) 18 (2–36) 18 (1–20) 0.8623
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Figure 1: Event-free Survival A. and overall survival B. from diagnosis. NCAT: Neoadjuvant chemotherapy followed by 
adjuvant trastuzumab; NCT: Neoadjuvant chemotherapy delivered with concomitant trastuzumab.
Table 3: Summary of efficacy endpoints - 5 years by treatment from diagnosis
All patients 
(n = 236)
NCT (n = 98) NCAT (n = 138) Hazard Ratio p
5-Year Overall 
Survival 77.4% (70.2, 83.1) 83.3% (66.2, 92.2) 74.0% (65.0, 81.1) 0.70 (0.34, 1.44) 0.336
5-Year Event-free 
Survival 63.7% (55.8, 70.5) 69.6% (51.5, 82.0) 59.3% (49.8, 67.6) 0.63 (0.37, 1.08) 0.091
5-Year Breast 
Cancer Specific 
Survival
80.3% (73.7, 86.1) 84.8% (70.8, 94.4) 77.9% (69.9, 85.0) 0.72 (0.33, 1.56) 0.408
Odds Ratio p
Total pCR Rate 
(n = 230) 19.6% (45) 33.3% (31) 10.2% (14) 4.39 (2.18, 8.86) <0.001
Breast pCR Rate 23.3% (55) 38.8% (38) 12.3% (17) 4.51 (2.35, 8.64) <0.001
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subgroup [22]. However, 55% of cases with HER2-positive 
tumours included in the meta-analysis did not receive AT 
as they were treated before it became standard of care. In 
those treated with trastuzumab, the women with hormone 
receptor- negative tumours achieving a pCR had the most 
favourable EFS and OS for all subgroups [22]. Previous 
studies of HER2 directed therapy within the neoadjuvant 
setting have not investigated the effect of sequencing HER2 
therapy relative to surgery in the neoadjuvant setting, the 
current study being the first to investigate this question. The 
present findings demonstrate that the commencement of 
trastuzumab in the neoadjuvant setting was associated with 
a trend towards increased EFS and OS with hazard ratios 
0.63 and 0.70 respectively. Univariable and multivariable 
analysis of the whole cohort showed no difference in 
clinical outcome with regard to the concomitant adjuvant 
use of trastuzumab as compared to sequential neoadjuvant 
use. However, significant differences in EFS were seen 
based on ER status, with a clear benefit from concomitant 
as opposed to sequential use of trastuzumab in women 
with ER negative disease but no benefit seen in women 
with ER positive tumours. It is an accepted notion that for 
HER2-posiitve breast cancer ER-positive disease and ER-
negative disease are two distinct entities, as reflected in the 
differences in pCR rates in neoadjuvant setting [3, 17–21] 
and differences seen in patterns and incidence of relapse 
within adjuvant studies [23]. Possible reasons therefore for 
the differential benefit observed in women with ER-negative 
disease with regard to the concomitant use of trastuzumab 
include the synergistic intetraction of chemotherapy and 
trastuzumab including docetaxel and trastuzumab [24]. As 
well as the earlier introduction of targeted therapy in this 
high-risk group of patients. It is notable that a concomitant 
trastuzumab regimen resulted in exposure to trastuzumab 
almost 5 months earlier, on average, than sequential post-
operative approach. Such delays may have been clinically 
significant in high risk tumour. While in women with 
HER2-positive, ER-positive disease the post-operative 
combination of endocrine therapy and trastuzumab, may 
have mitigated against any possible issues associated with 
the delayed start of trastuzumab.
The NCCTG N9831 trial is the only adjuvant 
study which has investigated the effect of concurrent 
versus sequential administration of trastuzumab with 
chemotherapy [9]. The estimated 5-year DFS favoured the 
sequential arm although this did not reach pre-specified 
levels of statistical significance. Interestingly, the hazard 
ratio with regard to EFS (HR: 0.63: 95% CI 0.37–1.08) 
observed in our study is similar to N9831 (HR: 0.77: 95% 
CI, 0.53–1.11), and favours commencing trastuzumab 
concomitantly with chemotherapy. As no multivariable 
analysis was presented within N9831, the effect of ER 
status on the relative benefit of concomitant versus 
sequential AT cannot be discerned [9].
Weaknesses of this study include the nonrandomised 
retrospective cohort design although randomised data 
addressing this question are unlikely to emerge. Overall 
the cohorts appeared well balanced although significant 
differences in the chemotherapy regimens were also noted 
with increased taxane use in the NCT group that may also 
have contributed to improved outcomes in this cohort [25]. 
On the other hand the true effect of NCT versus NCAT may 
have been underestimated as case ascertainment required 
patients to have received at least one cycle of trastuzumab 
and any patient relapsing prior to receiving the initial 
cycle of trastuzumab would have been excluded from the 
study. The time from diagnosis to first trastuzumab was 
significantly longer in the NCAT than the NCT group at 8.4 
versus 3.4 months, potentially overestimating the efficacy 
of NCAT via a guarantee-time bias effect [26]. Indeed, a 
number of cases of relapse prior to commencing AT were 
noted in some of the centres involved (data not presented).
Table 4: Summary of efficacy endpoints - 5 years by estrogen receptor status from diagnosis; ER: 
Estrogen Receptor
All patients 
(n = 236)
ER + (n = 124) ER − (n = 111) Hazard Ratio p
5-Year Overall 
Survival 77.4% (70.2, 83.1) 85.5% (75.3, 91.7) 69.1% (57.7, 78.0) 2.97 (1.59, 5.56) 0.001
5-Year Event-free 
Survival 63.7% (55.8, 70.5) 70.7% (59.7, 79.2) 56.5% (44.7, 66.6) 2.02 (1.26, 3.26) 0.004
5-Year Breast 
Cancer Specific 
Survival
80.3% (73.7, 86.1) 87.5% (78.8, 93.8) 72.0% (61.9, 81.4) 3.08 (1.58, 6.00) 0.001
Odds Ratio p
Total pCR Rate 
 (n = 230) 19.7% (45) 16.4% (20) 23.4% (25) 1.55 (0.81, 3.00) 0.187
Breast pCR Rate 23.3% (55) 18.6% (23) 28.8% (32) 1.78 (0.97, 3.28) 0.065
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In conclusion, concomitant as compared to 
sequential trastuzumab is associated with improved 
outcomes in the neoadjuvant setting for women with 
ER negative/HER2 positive tumours. These data are 
hypothesis generating but support the concept of early 
initiation of targeted combination therapy in women with 
ER negative/HER2 positive breast cancers.
PATIENTS AND METHODS
Identification of HER 2-positive neoadjuvant 
patients
HER-2 positive patients treated with neoadjuvant 
chemotherapy between January 2006 and December 2011 
at Imperial College Healthcare NHS Trust, West Middlesex 
Hospital, Ealing Hospital, Beatson West of Scotland Cancer 
Centre, breast units in the Greater Manchester and Cheshire 
Cancer Network, Bristol Oncology Centre and Institut Jules 
Bordet, Brussels were identified. Eligible patients had to 
have received at least one cycle of trastuzumab in either 
the neoadjuvant or adjuvant setting. Patients presenting or 
found to have metastatic disease were excluded.
HER2 Positivity
HER2 positivity was determined by 
Immunohistochemistry (IHC) and/or Silver in-situ 
hybridisation (SISH) or Fluorescence in-situ hybridisation 
(FISH) analyses according to local protocols.
Figure 2: Overall survival from surgery in patients with pathologic complete response (pCR) and without pCR A. and 
based on Estrogen receptor status/pCR interaction B.
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Data collection
Data collected included patient age, date and type 
of surgery, histologic grade and tumour size, lymph node 
involvement, estrogen and progesterone receptor status, details 
of neoadjuvant chemotherapy and the temporal relationship 
to initiation of trastuzumab with regard to chemotherapy 
and surgery. Tumour size was based on pre-treatment 
measurements; radiological (mammography/ultrasound) 
where possible with clinical measurements used where 
radiological measurements were not available. Details of 
disease-specific relapse and death, as well as non-breast cancer 
deaths, were also recorded. Patients entered into the “Adjuvant 
Lapatinib And/Or Trastuzumab Treatment Optimisation” 
(ALTTO) trial were excluded from the efficacy analysis.
Event-free survival (EFS), an event was defined 
as new primary breast cancer, local recurrence, distant 
relapse or death from any cause prior to recurrence/relapse 
and was calculated from the date of initial diagnosis and 
from date of surgery. Patients without recurrence at the 
date of last follow-up or treatment were censored. Overall 
survival (OS) was defined as death from any cause and 
breast cancer specific survival (BCSS) was defined as 
death related to breast cancer; both OS and BCSS were 
calculated from the date of diagnosis and from date of 
surgery. Patients without an event were censored at the 
date of last follow up, telephone contact or treatment visit. 
Data were locked for analysis on the 14th February, 2014.
Pathological complete response was defined as the 
complete absence of invasive disease in the breast (ypT0-is) 
Figure 3: Event-free survival from surgery in patients with pathologic complete response (pCR) and without pCR A. 
and based on Estrogen receptor status/pCR interaction B.
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Table 5: Surgical variables
Surgery
Variable All patients (n = 236) NCT (n = 98) NCAT (n = 138) p-value
Type of Surgery:
 Mastectomy 172 (72.9) 69 (70.4) 103 (74.6)
 Breast Conserving 60 (25.4) 28 (28.6) 32 (23.3)
 ANC only 4 (1.7) 1 (1.0) 3 (2.2) 0.537
Residual Disease in Breast:
 < 20 mm 170 (72.0) 74 (75.5) 96 (69.6)
 20–50 mm 42 (17.8) 16 (16.3) 26 (18.8)
 > 50 mm 15 (6.4) 4 (4.1) 11 (8.0)
 Not Available 9 (3.8) 4 (4.1) 5 (3.6) 0.616
Lymph Node Status:
 0 121 (51.3) 67 (68.4) 54 (39.1)
 1–3 59 (25.0) 16 (16.3) 43 (31.2)
 4–9 35 (14.8) 7 (7.1) 28 (20.3)
 ≥10 15 (6.4) 3 (3.1) 12 (8.7)
 Missing 6 (2.5) 5 (5.1) 1 (0.7) <0.001
Figure 4: Multivariable cox regression-Event-Free Survival from diagnosis A. with interaction B. CI: Confidence 
Interval; HR: hazard ratio; ER:Estrogen Receptor; NCAT: Neoadjuvant chemotherapy followed by adjuvant 
trastuzumab; NCT: Neoadjuvant chemotherapy delivered with concomitant trastuzumab.
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and absence of involved axillary lymph nodes (ypT0-is, 
pN0). The latter was defined as total pCR.
Statistical analyses
Multivariable Cox regression models [27] stratified 
by centre, were used to estimate adjusted hazard ratios. 
Where surgical covariates were included in survival 
analyses, landmark analysis (time from surgery) was 
used. Multivariable logistic regression was used to 
estimate adjusted odds ratios for the relationship between 
baseline covariates and pCR. For all multivariable analysis 
a stepwise model selection procedure using Akaike’s 
Information Criterion [28] was used to identify covariates 
to be included alongside treatment in the final model. 
The candidate variables for analysis from diagnosis and 
pCR were the baseline covariates; age, tumour size (mm), 
tumour grade and ER status. Landmark analysis [29] 
included further surgical covariates; tumour size (post-op), 
chemotherapy regimen, pCR status and surgery type. Once 
a final model was identified, various two-way interaction 
terms were explored and retained if p < 0.05.
Statistical analyses
Categorical variables are presented as frequency 
(percentage) and continuous variables as mean (SD). 
Survivor functions were estimated using the Kaplan-
Meier method [30] and compared using the log-rank test 
[31], stratifying by centre. Multivariable Cox regression 
models stratified by centre, were used to estimate adjusted 
hazard ratios. Where surgical covariates were included in 
survival analyses, landmark analysis (time from surgery) 
was used. Multivariable logistic regression was used to 
estimate adjusted odds ratios for the relationship between 
baseline covariates and pCR. For all multivariable analysis 
a stepwise model selection procedure using Akaike’s 
Information Criterion was used to identify covariates to 
be included alongside treatment in the final model. The 
candidate variables for analysis from diagnosis and pCR 
were the baseline covariates; age, tumour size (mm), 
tumour grade and ER status. Landmark analysis (3) 
included further surgical covariates; tumour size (post-op), 
chemotherapy regimen, pCR status and surgery type. Once 
a final model was identified, various two-way interaction 
terms were explored and retained if p < 0.05. All statistical 
analyses were conducted using Stata 13 (StataCorp. 2013).
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delivered with concomitant trastuzumab; pCR: pathologic complete response; WLE: Wide local excision.
Oncotarget13219www.impactjournals.com/oncotarget
REFERENCES
1. Piccart-Gebhart M, Procter M, Leyland-Jones B, 
Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, 
Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, 
et al. Trastuzumab after Adjuvant Chemotherapy in HER2-
Positive Breast Cancer. N Engl J Med. 2005; 353:1659–72.
2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE J, 
Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, 
Swain SM, Pisansky TM, Fehrenbacher L, et al. 
Trastuzumab plus adjuvant chemotherapy for operable 
HER2-positive breast cancer. New Engl J Med. 2005; 
353:1673–84.
3. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, 
Theriault RL, Pusztai L, Green MC, Singletary SE, 
Hunt KK, Sahin AA, Esteva F, Symmans WF, et al. 
Neoadjuvant therapy with paclitaxel followed by 5-fluoro-
uracil, epirubicin, and cyclophosphamide chemotherapy and 
concurrent trastuzumab in human epidermal growth factor 
receptor 2-positive operable breast cancer: an update of the 
initial randomized study population and data of additional 
patients treated with the same regimen. Clin Cancer Res. 
2007; 13:228–33.
4. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, 
Tjulandin S, Zambetti M, Vazquez F, Byakhow M, 
Lichinitser M, Climent MA, Ciruelos E, Ojeda B, et al. 
Neoadjuvant chemotherapy with trastuzumab followed by 
AT versus neoadjuvant chemotherapy alone, in patients 
with HER2-positive locally advanced breast cancer (the 
NOAH trial): a randomised controlled superiority trial 
with a parallel HER2-negative cohort. Lancet. 2010; 
375:377–84.
5. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, 
Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, 
Lichinitser M, Climent MA, Ciruelos E, Ojeda B, et al. 
Neoadjuvant and adjuvant trastuzumab in patients with 
HER2-positive locally advanced breast cancer (NOAH): 
follow-up of a randomised controlled superiority trial with 
a parallel HER2-negative cohort. Lancet Oncol. 2004; 
15:640–7.
6. Semiglazov V, Eiermann W, Zambetti M, Manikhas A, 
Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, 
Valagussa P, Baselga J, Gianni L. Surgery following neo-
adjuvant therapy in patients with HER2-positive locally 
advanced or inflammatory breast cancer participating in the 
NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol. 
2011; 37:856–63.
7. Palmieri C, Shah D, Krell J, Gojis O, Hogben K, Riddle P, 
Ahmad R, Tat T, Fox K, Porter A, Mahmoud S, Kirschke S, 
Shousha S, et al. Management and outcome of HER2-
positive early breast cancer treated with or without trastu-
zumab in the adjuvant trastuzumab era. Clin Breast Cancer. 
2011; 11:93–102.
8. Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, 
Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, 
Lortholary A, Orfeuvre H, Campone M, et al. Trastuzumab 
for patients with axillary-node-positive breast cancer: 
Results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009; 
27:6129–34.
9. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman 
PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, 
Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential 
versus concurrent trastuzumab in adjuvant chemotherapy 
for breast cancer. J Clin Oncol. 2011; 29:4491–97.
10. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, 
Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, 
Im SA, Pedrini JL, Poirier B, Morandi P, et al. Efficacy 
and safety of neoadjuvant pertuzumab and trastuzumab 
in women with locally advanced, inflammatory, or early 
HER2-positive breast cancer (NeoSphere): a randomised 
multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 
13:25–32.
11. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, 
Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, 
Ewer MS, Hunt KK. Fluorouracil, epirubicin, and cyclo-
phosphamide (FEC-75) followed by paclitaxel plus trastu-
zumab versus paclitaxel plus trastuzumab followed by FEC-
75 plus trastuzumab as neoadjuvant treatment for patients 
with HER2-positive breast cancer (Z1041): a randomised, 
controlled, phase 3 trial. Lancet Oncol. 2013; 14:1317–25.
12. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, 
Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, 
Margolese RG, Farrar WB, Brufsky AM, et al. Lapatinib as a 
component of neoadjuvant therapy for HER2-positive oper-
able breast cancer (NSABP protocol B-41): an open-label, 
randomised phase 3 trial. Lancet Oncol. 2013; 14:1183–92.
13. Carey LA, Berry DA, Ollila D, Harris L, Kropet IE al. 
Clinical and translational results of CALGB 40601. 2013; 
ASCO Annual Meeting. Abstract 500Presented June 2 
2013.
14. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, 
Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, 
Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. 
Pathologic complete response to neoadjuvant chemotherapy 
with trastuzumab predicts for improved survival in women 
with HER2-overexpressing breast cancer. Ann Oncol. 2013; 
24:1999–2004.
15. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, 
Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, 
Smith I, Boyle F, Xu B, Barrios CH, et al. Lapatinib 
with trastuzumab for HER2-positive early breast cancer 
(NeoALTTO): survival outcomes of a randomised, open-
label, multicentre, phase 3 trial and their association with 
pathological complete response. Lancet Oncol. 2014; 
15:1137–46.
16. Huang L, Chen S, Yang W, Xu B, Huang T, Yang H, Zheng H, 
Wang Y, Song E, Zhang J, Cui S, Pang D, Tang L, Lei Y, 
Geng C, Shao Z. Efficacy and safety analysis of trastu-
zumab and paclitaxel based regimen plus carboplatin or 
epirubicin as neoadjuvant therapy for clinical stage II-III, 
Oncotarget13220www.impactjournals.com/oncotarget
HER2-positive breast cancer patients: a phase 2, open-
label, multicenter, randomized trial. Oncotarget. 2015; 
6:18683–92. doi: 10.18632/oncotarget.4337.
17. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, 
Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, 
Kühn T, du Bois A, et al. Neoadjuvant treatment with 
trastuzumab in HER2-positive breast cancer: results from 
the GeparQuattro study. J Clin Oncol. 2010; 28:2024–31.
18. Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, 
Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, 
Stickeler E, Harbeck N, Höss C, et al. Pathologic complete 
response after neoadjuvant chemotherapy plus trastuzumab 
predicts favorable survival in human epidermal growth fac-
tor receptor 2-overexpressing breast cancer: results from the 
TECHNO trial of the AGO and GBG study groups. J Clin 
Oncol. 2011; 29:3351–57.
19. Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, 
Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, 
Untch M, Orlando L, Artioli F, et al. Preoperative chemo-
therapy plus trastuzumab, lapatinib, or both in human epi-
dermal growth factor receptor 2-positive operable breast 
cancer: results of the randomized phase II CHER-LOB 
study. J Clin Oncol. 2012; 30:1989–95.
20. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, 
Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, 
Kreienberg R, Tesch H, Hanusch C, Gerber B, et al. 
Lapatinib versus trastuzumab in combination with neo-
adjuvant anthracycline-taxane-based chemotherapy 
(GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet 
Oncol. 2012; 13:135–44.
21. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de 
Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van 
Dooren V, Aktan G, Goldhirsch A, Chang TW, et al. 
Lapatinib with trastuzumab for HER2-positive early breast 
cancer (NeoALTTO): a randomised, open-label, multicen-
tre, phase 3 trial. Lancet. 2012; 379:633–40.
22. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, 
Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, 
Swain SM, Prowell T, Loibl S, et al. Pathological complete 
response and long-term clinical benefit in breast cancer: the 
CTNeoBC pooled analysis. Lancet. 2014; 384:164–72.
23. O’Sullivan CC, Bradbury I, Campbell C, Spielmann M, 
Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, 
Zardavas D, Ballman KV, Holmes E, de Azambuja E, 
Piccart-Gebhart M, Zujewski JA, Gelber RD. Efficacy of 
Adjuvant Trastuzumab for Patients With Human Epidermal 
Growth Factor Receptor 2-Positive Early Breast Cancer 
and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized 
Trastuzumab Trials. J. Clin Oncol. 2015; Jun 22. [Epub 
ahead of print].
24. Pegram MD, Konecny GE, O’Callaghan C, Beryt M, 
Pietras R, Slamon DJ. Rational combinations of trastu-
zumab with chemotherapeutic drugs used in the treatment 
of breast cancer J Natl Cancer Inst. 2004; 96:739–49.
25. Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG). Comparisons between different polychemo-
therapy regimens for early breast cancer: meta-analyses 
of long-term outcome among 100,000 women in 123 ran-
domised trials. Lancet. 2012; 379:432–44.
26. Giobbie-Hurder A, Gelber RD, Regan MM. Chall-
enges of guarantee-time bias. J Clin Oncol. 2013; 
31:2963–2969.
27. Cox DR. Regression Models and Life-Tables. J R Stat Soc 
Ser B. 1972; 34:187–220.
28. Akaike H. A new look at the statistical model identification. 
Automatic Control, IEEE Trans. 1974; 19:716–723.
29. Marubini E, Valsecchi MG. Analysing Survival Data from 
Clinical Trials and Observational Studies. John Wiley & 
Sons; ChichesterWest Sussex, England: 2004.
30. Kaplan EL, Meier P. Nonparametric estimation from 
incomplete observations. J. Amer. Statist. Assn. 1958; 
53:457–81.
31. Peto R, Peto J. Asymptotically efficient rank invariant test 
procedures. J R Stat Soc Ser, A. 101972; 35:185–207.
